Reclast (Zoledronic Acid) for Children Under 12: School and Activity Guide for Parents

Why a Child Under 12 Might Be Prescribed Zoledronic Acid

Zoledronic acid is not a standard medication for healthy children. It is reserved for pediatric patients with documented low bone mineral density (BMD) or fragility fractures caused by a specific underlying condition. The most common diagnoses driving this prescription are osteogenesis imperfecta (OI), glucocorticoid-induced osteoporosis from long-term steroid therapy, and secondary osteoporosis linked to conditions such as cerebral palsy, leukemia, or inflammatory bowel disease.

Which Girls Are Most Likely to Be in This Situation

Girls carry specific risk factors that make low childhood BMD more common than many parents expect.

• Girls with Turner syndrome (45,X karyotype) have impaired estrogen production and achieve lower peak bone mass. The Pediatric Endocrine Society recommends monitoring BMD in this group from childhood.
• Girls treated with glucocorticoids for juvenile idiopathic arthritis, lupus, or nephrotic syndrome lose bone at rates that can reach up to 5 percent per year of steroid exposure.
• Girls with anorexia nervosa frequently present with vertebral BMD Z-scores below -2.0 by age 10 to 12, a threshold that may trigger bisphosphonate consideration in refractory cases.
• Girls with moderate-to-severe OI sustain an average of 1.9 long-bone fractures per year before bisphosphonate treatment, a number that bisphosphonate therapy reduces substantially.

The Evidence Base: What Trials Say About Children Under 12

Zoledronic acid in children is studied in OI and glucocorticoid-induced bone loss. The HORIZON Key Fracture Trial was conducted in postmenopausal women, so pediatric dosing is extrapolated from smaller studies. The largest randomized controlled trial specific to OI children, published in the New England Journal of Medicine in 2013, compared zoledronic acid to pamidronate and found equivalent gains in lumbar spine BMD Z-score (mean increase of 0.71 with zoledronic acid versus 0.76 with pamidronate at 24 months) with fewer infusion days.

A practical framework: think of zoledronic acid not as curing the underlying disease but as buying time for a child's skeleton to accumulate bone while the primary condition is managed. School and activity decisions must account for both the drug's post-infusion effects AND the fracture risk imposed by the underlying diagnosis.

How Zoledronic Acid Is Given to Children and What the First Few Days Look Like

Pediatric zoledronic acid is administered intravenously, typically as a 30-to-45-minute infusion in a hospital or outpatient infusion center. The standard pediatric dose is 0.025 to 0.05 mg/kg, not the 5 mg flat dose used in postmenopausal osteoporosis. Children under 20 kg often receive the lower end of this range.

Pre-Infusion Preparation That Affects School Planning

The care team will ask your child to:

1. Be well-hydrated before arrival (sometimes IV fluids are started 30 minutes before the drug).
2. Take oral ibuprofen or acetaminophen 30 to 60 minutes before infusion to blunt the acute phase response.
3. Have calcium and vitamin D levels checked beforehand. Hypocalcemia must be corrected before any dose because zoledronic acid can worsen it acutely.

Scheduling the infusion on a Wednesday or Thursday lets the first 48 to 72 hours of potential fever and achiness fall over a school week rather than consuming a full weekend of family plans.

The Acute Phase Reaction: What to Tell the School

Roughly 30 to 40 percent of children experience an acute phase reaction after the first zoledronic acid infusion. Symptoms include:

• Fever (sometimes up to 39.5°C / 103.1°F)
• Muscle and joint aches
• Fatigue and irritability
• Headache
• Nausea, occasionally vomiting

This reaction is immune-mediated, driven by release of inflammatory cytokines, and is not an allergic reaction. It peaks at 24 to 48 hours and typically resolves by 72 hours. Subsequent infusions produce this reaction in a much smaller fraction of children, roughly 10 to 15 percent by the second dose.

Plan to keep your child home from school for 3 to 5 days after the first infusion. After the second and subsequent infusions, 1 to 2 days at home is usually enough if prior infusions were well-tolerated. Write a short note to the school explaining a scheduled medical procedure requiring a brief recovery period. You do not need to disclose the diagnosis if you prefer privacy.

Returning to School: Practical Logistics

Once your child is past the acute phase reaction window, there are no drug-specific reasons to restrict school attendance. Zoledronic acid does not impair cognition, cause sedation, or interact with common classroom medications.

What the School Nurse Needs to Know

Share the following with the school nurse before your child returns:

• The child's underlying diagnosis and any fracture risk classifications given by the orthopedic or metabolic bone team.
• Any weight-bearing restrictions currently in place.
• Whether the child wears orthotics, uses a walker, or has wheelchair needs.
• Emergency contacts if a fall injury occurs at school.
• A written action plan for managing a suspected fracture (who to call, whether the child should be moved or kept still).

The school nurse does not need to administer any ongoing medication related to zoledronic acid itself. If your child takes daily calcium and vitamin D supplements, those can be brought in per standard medication policy.

IEP or 504 Plan Considerations

A child receiving zoledronic acid for a condition like OI, lupus, or cerebral palsy almost certainly qualifies for a Section 504 plan or an Individualized Education Program (IEP) if the underlying condition affects a major life activity. A 504 plan can formalize:

• Seating arrangements that reduce fall risk (aisle seats, proximity to the exit, chair with armrests).
• Permission to leave class early to avoid hallway crowding.
• Elevator access.
• Modified physical education as documented by the care team.
• Excused absences for infusion appointments without academic penalty.

Ask your hospital's social worker or the school's special education coordinator to help initiate the process. The American Academy of Pediatrics policy on children with special health care needs in schools provides a framework that schools are required to follow.

Physical Activity and Sports: What Is Actually Restricted

This is one of the most misunderstood areas. Zoledronic acid itself does not impose activity restrictions. The drug is not sedating, does not cause muscle weakness, and does not alter balance. Activity limits come entirely from:

1. The child's underlying diagnosis and current fracture status.
2. Any active healing fractures.
3. Orthopedic team guidance specific to bone density Z-scores and fracture history.

Activity Categories and General Guidance

The pediatric orthopedic community generally uses a tiered approach. This is not a standardized national guideline but reflects common clinical practice at major pediatric bone programs:

Low-risk activities (generally permitted unless there is an active fracture):

• Swimming
• Stationary cycling
• Walking on flat surfaces
• Seated classroom art, music, drama

Moderate-risk activities (require orthopedic clearance):

• Hiking on uneven terrain
• Dance classes
• Recreational gymnastics at low impact
• Yoga and stretching classes

High-risk activities (typically restricted in children with OI or severe secondary osteoporosis):

• Contact sports: soccer, basketball, football, martial arts
• Trampoline use (associated with a high rate of fracture in OI children specifically)
• Skiing, snowboarding
• Competitive gymnastics or cheerleading with tumbling

A child who has been fracture-free for 24 months, whose lumbar spine BMD Z-score has improved to above -1.5, and who carries a low-impact diagnosis may be cleared for moderate activities by her orthopedic team. These decisions are made on a case-by-case basis.

Physical Education at School

Work with the PE teacher before the school year starts. Ask the care team for a brief letter specifying:

• Which activities are permitted.
• What alternative activities are appropriate on high-risk days.
• Whether the child can participate as a scorer, timekeeper, or team manager during restricted activities.

A child who cannot play contact sports can still build friendships, feel included, and maintain physical conditioning through swimming or cycling programs.

Monitoring During Treatment: What School and Home Need to Track

Children on zoledronic acid have scheduled monitoring visits, typically at 6-to-12-month intervals.

Lab Monitoring

The care team monitors:

• Serum calcium and phosphate (risk of hypocalcemia is highest in the 48 hours after infusion)
• 25-hydroxyvitamin D level
• Parathyroid hormone
• Urine calcium-to-creatinine ratio
• Renal function (serum creatinine), because zoledronic acid is renally cleared and is contraindicated if eGFR is below 35 mL/min/1.73m²

Parents should know the signs of hypocalcemia: muscle cramps, tingling around the mouth, and in severe cases, facial muscle twitching (Chvostek's sign). If these occur in the 24 to 48 hours after infusion, the child needs same-day medical evaluation.

Imaging Monitoring

DXA scans are repeated every 12 to 24 months to measure BMD Z-score change. In children, the International Society for Clinical Densitometry (ISCD) pediatric guidelines specify that low bone mass is defined as a Z-score at or below -2.0, and that the diagnosis of "osteoporosis" in children requires both low BMD and a clinically significant fracture history. BMD Z-score alone is not sufficient for diagnosis.

Spine radiographs may be taken periodically to identify vertebral compression fractures, which are often clinically silent and detectable only on imaging.

Girls-Specific Considerations Across Life Stages

Although this article focuses on children under 12, the sex-specific context matters for long-term care planning for girls.

Why Girls' Bone Accrual Is Different From Boys'

Peak bone mass accrual in girls occurs between ages 11 and 14, coinciding with pubertal estrogen rise. A girl who misses this window due to delayed puberty, eating disorder, or estrogen deficiency (as in Turner syndrome or premature ovarian insufficiency) enters adulthood with a substantially lower bone bank. Approximately 40 to 60 percent of peak bone mass is accrued in the three years surrounding peak height velocity, which typically occurs 2 years earlier in girls than in boys. This means that treating low BMD in a 9- or 10-year-old girl carries particular urgency relative to treating the same Z-score in a boy of the same age.

Hormonal Status and Drug Interaction

In girls who are pre-pubertal, there is no estrogen-bisphosphonate interaction to manage. Girls who begin puberty during zoledronic acid therapy do not require dose adjustments, but the care team may add low-dose estrogen therapy in cases of delayed puberty, since estrogen and bisphosphonates act through different mechanisms and are used together safely in Turner syndrome management per ACOG Committee Opinion No. 783.

Girls with menstrual irregularity at age 11 to 12 should have their hormonal status evaluated, since anovulatory cycles and low estrogen exposure during perimenarchal years amplify bone loss.

Pregnancy, Lactation, and Contraception: Required Safety Information

Zoledronic acid is contraindicated in pregnancy. This section is included because girls currently under 12 will eventually reach reproductive age, and transition planning must address this.

Animal studies show teratogenicity at doses below the human therapeutic dose, including fetal abnormalities and fetal growth restriction. FDA labeling classifies zoledronic acid as pregnancy category D (now described under the PLLR as having evidence of human fetal risk based on adverse reaction reports and animal data). There are documented cases of neonatal hypocalcemia and skeletal anomalies following inadvertent use in pregnancy.

Bisphosphonates are incorporated into bone matrix and continue to be released into the circulation for months to years after treatment ends. The half-life of zoledronic acid in bone is estimated at more than 10 years. For this reason, women planning pregnancy are counseled to allow a drug holiday of at least 1 to 2 years before conception, although no human data define a safe washout interval precisely.

Lactation transfer of zoledronic acid is not well-characterized in humans. Animal data suggest minimal transfer into breast milk, but given the bone half-life and potential fetal/infant skeletal effects, zoledronic acid is not recommended during breastfeeding.

For adolescent girls transitioning off pediatric zoledronic acid therapy, clinicians should:

1. Document total cumulative dose and duration of therapy.
2. Counsel on the need for reliable contraception if treatment continues into reproductive years.
3. Refer to a reproductive endocrinologist if pregnancy planning is anticipated within 2 to 3 years of last infusion.
4. Avoid bisphosphonates during pregnancy and lactation without a multidisciplinary risk-benefit discussion.

Who This Treatment Is Right for (and Who It Is Not)

Children Most Likely to Benefit

• Documented OI (types III, IV, V) with two or more long-bone fractures in the preceding 12 months.
• Glucocorticoid-induced osteoporosis with a lumbar spine Z-score at or below -2.0 and either a vertebral fracture or ongoing high-dose steroid requirement.
• Turner syndrome with estrogen deficiency and BMD Z-score at or below -2.0, when estrogen therapy alone has not reversed bone loss.
• Secondary osteoporosis from childhood cancer treatment (including cranial radiation that impairs GH and gonadal axes) with fractures.

Children for Whom Zoledronic Acid Is Not Appropriate

• Children without a documented low-BMD condition or fracture history. This is not a preventive drug for otherwise healthy children.
• Children with acute or active dental infections. Osteonecrosis of the jaw (ONJ) is rare in children but has been reported. A dental evaluation before starting therapy is standard of care.
• Children with significant renal impairment (eGFR below 35 mL/min/1.73m²), as the drug is renally cleared.
• Children with uncorrected hypocalcemia.
• Children in whom the underlying diagnosis (e.g., mild OI type I with zero fractures) does not meet established indications for bisphosphonate therapy, per ISCD pediatric position statements.

Prescribing bisphosphonates to a child is a decision that requires input from pediatric endocrinology, metabolic bone disease specialists, and often orthopedic surgery. General pediatricians and family medicine physicians typically refer rather than initiate this therapy.

Talking to Your Child About What to Expect

Children under 12 understand far more than adults often assume. Age-appropriate honesty reduces procedural anxiety and helps the child become an active participant in her own care.

For a 7-to-9-year-old, try: "You're getting a medicine through a small tube in your arm. It goes into your bones to help make them stronger. You might feel achy and tired for a couple of days, like when you have a cold, and then you'll start to feel normal again."

For a 10-to-12-year-old: "This medicine is called zoledronic acid. It slows down the cells that break down bone, so your bones can build up more thickness between now and when you're a teenager. Most kids feel like they have the flu for 2 or 3 days after. After that, there's no ongoing side effect you'll feel day-to-day."

Both messages are accurate and developmentally appropriate. The American Academy of Pediatrics recommends involving children in medical decision-making to the extent of their capacity, which improves adherence and long-term trust in the care relationship.

A school counselor or child psychologist can help a child process feelings about being "different" at school, especially if she uses mobility aids or has visible signs of her underlying condition.